ID: ALA316101

Max Phase: Preclinical

Molecular Formula: C31H37F4N3O7

Molecular Weight: 639.64

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCCCCCCc1ccc(NC(=O)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)COc2c(F)c(F)cc(F)c2F)C(C)C)cc1

Standard InChI:  InChI=1S/C31H37F4N3O7/c1-4-5-6-7-8-9-18-10-12-19(13-11-18)36-30(43)31(44)38-27(17(2)3)29(42)37-22(15-24(40)41)23(39)16-45-28-25(34)20(32)14-21(33)26(28)35/h10-14,17,22,27H,4-9,15-16H2,1-3H3,(H,36,43)(H,37,42)(H,38,44)(H,40,41)/t22-,27-/m0/s1

Standard InChI Key:  RQIIIOLCSXYOBO-CUNXSJBXSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 639.64

Molecular Weight (Monoisotopic): 639.2568

AlogP: 4.44

#Rotatable Bonds: 17

Polar Surface Area: 150.90

Molecular Species: ACID

HBA: 6

HBD: 4

#RO5 Violations: 1

HBA (Lipinski): 10

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 3.68

CX Basic pKa:

CX LogP: 5.94

CX LogD: 2.63

Aromatic Rings: 2

Heavy Atoms: 45

QED Weighted: 0.09

Np Likeness Score: -0.53

References

1. Linton SD, Aja T, Allegrini PR, Deckwerth TL, Diaz JL, Hengerer B, Herrmann J, Jahangiri KG, Kallen J, Karanewsky DS, Meduna SP, Nalley K, Robinson ED, Roggo S, Rovelli G, Sauter A, Sayers RO, Schmitz A, Smidt R, Ternansky RJ, Tomaselli KJ, Ullman BR, Wiessner C, Wu JC..  (2004)  Oxamyl dipeptide caspase inhibitors developed for the treatment of stroke.,  14  (10): [PMID:15109679] [10.1016/j.bmcl.2003.12.106]

2.  (2007)  C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases, 

Source

Source(2):

• Scientific Literature
• Patent Bioactivity Data